Elanco Animal Health (ELAN) Expected to Announce Quarterly Earnings on Friday

Elanco Animal Health (NYSE:ELAN) is projected to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Elanco Animal Health to announce earnings of $0.2028 per share and revenue of $1.21 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.26 earnings per share. On average, analysts expect Elanco Animal Health to post $1.13 EPS for the current fiscal year and $1.28 EPS for the next fiscal year.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $25.20 on Thursday. The firm has a market capitalization of $12.59 billion, a price-to-earnings ratio of -61.46, a PEG ratio of 2.18 and a beta of 1.73. The business has a 50 day simple moving average of $23.14 and a 200-day simple moving average of $23.82. Elanco Animal Health has a 1 year low of $19.40 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 price objective on the stock. Finally, Morgan Stanley dropped their target price on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Insiders Place Their Bets

In related news, Director Paul Herendeen bought 10,000 shares of the stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lawrence Kurzius bought 40,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were bought at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This trade represents a 26.91% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 63,198 shares of company stock valued at $1,473,109. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.